Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Translation in Brief

Delivering Model T CARs

How delivery technologies could give CAR therapies their Model T moment

April 26, 2017 11:04 PM UTC

A Fred Hutchinson Cancer Research Center team believes its two chimeric antigen receptor (CAR) delivery platforms could lower immunological and financial costs enough to turn engineered immune cell therapies into widely accessible treatments. With two studies on their implant- and nanoparticle-based CAR technologies published in the last two weeks, the researchers are seeking industry partners to turn both platforms into therapeutics.

Matthias Stephan, the principal investigator behind the studies, told BioCentury his goal was to broaden the use of CAR and other cellular immunotherapies by developing versions of the technologies that don't require wiping out the patient's immune system or growing tens of millions of cells in culture...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article